doxazosin has been researched along with Diabetic Glomerulosclerosis in 6 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 6.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| "Doxazosin was generally well-tolerated; four patients (29%) reported mild-to-moderate treatment-related adverse events." | 6.69 | Hand vein responses to noradrenaline in normotensive patients with insulin-dependent diabetes mellitus and microalbuminuria: effects of alpha-adrenoceptor blockade with doxazosin. ( Bodmer, CW; Lake, D; Savage, MW; Williams, G, 1999) |
| "Both doxazosin treatment and good glycemic control normalized these abnormalities in diabetic rats." | 5.29 | Doxazosin prevents proteinuria and glomerular loss of heparan sulfate in diabetic rats. ( Alluru, I; Jyothirmayi, GN; Reddi, AS, 1996) |
| "Enalapril, but not doxazosin, reduces albuminuria in insulin dependent diabetes mellitus patients with nephropathy." | 5.08 | Contrasting effects of angiotensin converting inhibitor and alpha-1-antagonist on albuminuria in insulin-dependent diabetes mellitus patients with nephropathy. ( Berg, KJ; Blystad, L; Fauchald, P; Hartmann, A; Holdaas, H; Langberg, H, 1995) |
| " We assessed the effects of doxazosin on 24-h BP and spectral analysis of heart rate variability in hypertensive Type 2 diabetic patients with macroalbuminuria and compared the results with those in hypertensive Type 2 diabetic patients with normoalbuminuria and non-diabetic patients with essential hypertension." | 3.73 | Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy. ( Hasegawa, K; Kuji, T; Ogawa, N; Shimura, G; Tochikubo, O; Umemura, S; Yasuda, G, 2005) |
| "Hydrochlorothiazide was then added for the subsequent 4 months." | 2.69 | Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. ( Half-Onn, E; Levi, Z; Rachmani, R; Ravid, M; Slavachevsky, I, 1998) |
| "Doxazosin was generally well-tolerated; four patients (29%) reported mild-to-moderate treatment-related adverse events." | 2.69 | Hand vein responses to noradrenaline in normotensive patients with insulin-dependent diabetes mellitus and microalbuminuria: effects of alpha-adrenoceptor blockade with doxazosin. ( Bodmer, CW; Lake, D; Savage, MW; Williams, G, 1999) |
| "Both doxazosin treatment and good glycemic control normalized these abnormalities in diabetic rats." | 1.29 | Doxazosin prevents proteinuria and glomerular loss of heparan sulfate in diabetic rats. ( Alluru, I; Jyothirmayi, GN; Reddi, AS, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yasuda, G | 1 |
| Hasegawa, K | 1 |
| Kuji, T | 1 |
| Ogawa, N | 1 |
| Shimura, G | 1 |
| Umemura, S | 1 |
| Tochikubo, O | 1 |
| Holdaas, H | 1 |
| Hartmann, A | 1 |
| Berg, KJ | 1 |
| Langberg, H | 1 |
| Blystad, L | 1 |
| Fauchald, P | 1 |
| Jyothirmayi, GN | 1 |
| Alluru, I | 1 |
| Reddi, AS | 2 |
| Rachmani, R | 1 |
| Levi, Z | 1 |
| Slavachevsky, I | 1 |
| Half-Onn, E | 1 |
| Ravid, M | 1 |
| Bodmer, CW | 1 |
| Lake, D | 1 |
| Savage, MW | 1 |
| Williams, G | 1 |
| Nimmagadda, VR | 1 |
| Lefkowitz, A | 1 |
| Kuo, HR | 1 |
| Bollineni, JS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for doxazosin and Diabetic Glomerulosclerosis
3 other studies available for doxazosin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Effects of doxazosin on ambulatory blood pressure and sympathetic nervous activity in hypertensive Type 2 diabetic patients with overt nephropathy.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Albuminuria; Blood Pressure; Blood Pre | 2005 |
Doxazosin prevents proteinuria and glomerular loss of heparan sulfate in diabetic rats.
Topics: Adrenergic alpha-Antagonists; Albuminuria; Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus | 1996 |
Effect of antihypertensive therapy on renal injury in type 2 diabetic rats with hypertension.
Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Typ | 2000 |